[Clinical efficacy of leponex according to the findings of an international study].
Leponex was used to treat 120 schizophrenic patients with doses varying from 50 to 550 mg and the course of therapy lasting for two months. Considerable specificities were revealed in the spectrum of the drug psychotropic activity and the nature of its side effects. Leponex was especially effective in cases of delirious, hallucinational and catatonic symptomatology. This drug was proved to be a method of choice in progressive protracted schizophrenic psychoses accompanied by the above disorders. The regimen of gradual and slow accretion of daily doses throughout the treatment with leponex utilized in this study is assessed as optimal for preventing the development of toxic side effects associated with the use of this drug.
D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D010054:Brief Psychiatric Rating Scale; D003024:Clozapine / Q000008:administration & dosage* / Q000009:adverse effects; D003702:Delusions / Q000188:drug therapy; D003984:Dibenzazepines / Q000008:administration & dosage*; D005260:Female; D006212:Hallucinations / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012560:Schizophrenia, Catatonic / Q000188:drug therapy
D014150:Antipsychotic Agents; D003984:Dibenzazepines; D003024:Clozapine
Klinicheskaia éffektivnost' leponeksa po dannym mezhdunarodnogo issledovaniia.